A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared to domestic drugs. The findings have drawn criticism from the Indian Pharmaceutical Alliance, which disputes the study’s methodology and its implications on quality and efficacy.